Clinical trials: Catamenial Epilepsy
Epilepsies, Partial
Open-label Extension to Protocol 1042-0600
To allow open-label extension to patients who have completed Protocol 1042-0600.
- Trial name
- NCT00512317
- Testing
- ganaxolone
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy
Progesterone vs Placebo Therapy for Women With Epilepsy
The purpose of this investigation was to determine if cyclic adjunctive progesterone supplement is superior to placebo in the treatment of intractable seizures in women with and without catamenial epilepsy.
- Trial name
- NCT00029536
- Testing
- Progesterone Lozenges
- Where
- 15 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Beth Israel Deaconess Medical Center
Catamenial Epilepsy
Fycompa in Catamenial Epilepsy
The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy.
- Trial name
- NCT05201703
- Testing
- Fycompa, Fycompa with a boost
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Partial Epilepsy, Catamenial Epilepsy
A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
- Trial name
- NCT00465517
- Testing
- Ganaxolone
- Where
- 27 sites in United States
- Volunteers
- 147 people
- Sponsor
- Marinus Pharmaceuticals